Amir Nashat, Ph.D., is a General Partner in the Boston office of Polaris Venture Partners. Prior to joining Polaris, Dr. Nashat completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. His doctoral research focused on information flow through neurons, neural implants, and neural tissue engineering. Dr. Nashat currently represents Polaris as a Director of aTyr Pharmaceuticals, BIND Biosciences, Fate Therapeutics, Living Proof, Pervasis Therapeutics, Promedior Pharmaceuticals and Selecta Biosciences. Amir played an instrumental role in the inception of Living Proof, Pervasis and Sun Catalytix Corporation, serving as the founding President of all three companies. Additionally, Amir has served as a Director of Avila Therapeutics (acquired by Celgene), Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), and Hydra Biosciences, and as an Observer of GI Dynamics and Advion.
Prior to obtaining his Ph.D. at MIT, Dr. Nashat earned both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.